Skip to main content
GemVax & KAEL Co.,Ltd. logo

GemVax & KAEL Co.,Ltd. — Investor Relations & Filings

Ticker · 082270 ISIN · KR7082270000 KO Manufacturing
Open in API
Filings indexed 651 across all filing types
Latest filing 2020-03-20 Management Reports
Country KR South Korea
Listing KO 082270

About GemVax & KAEL Co.,Ltd.

https://gemvax.com/

GemVax & KAEL is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics. Its lead drug candidate is GV1001, a synthetic peptide composed of 16 amino acids, which has demonstrated multiple actions including the modulation of neuroinflammation and reduction of oxidative stress. The company's development pipeline primarily targets neurodegenerative diseases, such as Alzheimer's disease and Progressive Supranuclear Palsy (PSP). Other therapeutic areas under investigation include pancreatic cancer and benign prostatic hyperplasia. GemVax & KAEL is actively advancing its programs through clinical trials to evaluate the efficacy and safety of its novel treatments.

Recent filings

Filing Released Lang Actions
[기재정정]의결권대리행사권유참고서류
Management Reports Classification · 95% confidence The document is a 'Correction Report' (정정신고) filed by GemVax & Kael Co., Ltd. regarding previously submitted 'Reference Documents' (참고서류) for a General Meeting of Shareholders. It contains detailed financial statements (balance sheets, income statements, and deficit disposal statements) for the 2019 fiscal year, presented as a comparison between 'Before Correction' and 'After Correction' versions. Since this document provides detailed financial data and management's explanation of financial results in the context of a shareholder meeting, it falls under the category of Management Reports (MDA), which covers management's detailed explanation of financial results and business trends.
2020-03-20 Korean
감사보고서제출
Audit Report / Information Classification · 95% confidence The document is a formal 'Audit Report Submission' (감사보고서 제출) filed by GemVax. It contains key financial data, audit opinions, and financial statements (consolidated and separate) for the fiscal year. While it provides financial highlights, it is a regulatory filing specifically reporting the receipt and submission of the audit report to the exchange, which is a standard requirement for public companies. Given the structure and content, it falls under the 'Audit Report / Information' category. FY 2019
2020-03-19 Korean
[기재정정]매출액또는손익구조30%(대규모법인은15%)이상변동
Audit Report / Information Classification · 95% confidence The document is a regulatory filing from a Korean company (GemVax) regarding a 'Correction Report' (정정신고) for a previously disclosed financial statement (specifically, a 30% or more change in revenue or profit/loss structure). This type of filing is a standard regulatory disclosure required by the Korea Exchange (KRX) when financial figures are updated due to audit results. Since it is a specific regulatory disclosure of financial changes rather than a full annual report, a quarterly report, or a simple announcement of a report, it falls under the 'Regulatory Filings' category. FY 2019
2020-03-19 Korean
[기재정정]파생상품거래손실발생
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from a Korean company (GemVax) regarding a correction (amendment) to a previously disclosed report about derivative transaction losses. It follows the standard format of a DART (Data Analysis, Retrieval and Transfer System) filing, which is the Korean equivalent of the SEC's EDGAR system. Since it is a specific regulatory disclosure regarding financial adjustments and does not fit into categories like Annual Reports, Earnings Releases, or M&A, it is classified as a general Regulatory Filing (RNS).
2020-03-19 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Management Reports Classification · 95% confidence The document is a regulatory filing from a Korean company (GemVax) disclosing a significant change (over 30%) in revenue or profit/loss structure. This type of disclosure is a standard regulatory requirement in the Korean market (KRX) for listed companies to report material financial changes. It provides specific financial data, reasons for the variance, and board approval details. It is not a full annual report, but rather a specific regulatory disclosure of financial performance, fitting best under the 'Regulatory Filings' category.
2020-03-12 Korean
파생상품거래손실발생
Capital/Financing Update Classification · 95% confidence The document is a regulatory disclosure from a Korean company (GemVax) regarding a 'Loss from Derivative Transactions' (파생상품거래손실발생). It details financial losses related to convertible bonds and derivative valuations. Since this is a specific regulatory disclosure of a material financial event that does not fit into categories like earnings releases, annual reports, or shareholder communications, it falls under the general regulatory filing category.
2020-03-12 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.